CPSF3

Across TCGA pan-cancer cohorts, CPSF3 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated CPSF3 data layer compared with 23 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher CPSF3 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated CPSF3 expression acts as an unfavorable survival marker, although some lineages such as COAD and LUAD show a favorable association.

CCRCC, COAD, and LUAD are the cancer types where CPSF3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Median	III,IV	0.315	0.810	<.001	48	view →
COAD	DFS	Median	All	1.000	0.888	.023	12	view →
LUAD	OS	Quartile	III,IV	0.925	0.311	.019	9	view →
PDAC	DFS	Median	III,IV	0.216	0.494	.021	4	view →
HNSC	OS	Quartile	All	0.834	0.959	.027	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

CPSF3–CCRCC (DFS)

Open the CCRCC breakdown →